Based on this YouTube video's total view count of 6.56K views and industry-standard rates, the estimated total earning is $5 - $13 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Veru CEO: Cancer drug has potential to prevent Covid-19 deaths with 6,560 views, 81 likes, and 15 comments. Experience the impact of this video content that has captured audience attention.

Veru CEO Dr. Mitchell Steiner explained how VERU-111, a prostate cancer drug developed by the biotech company, could be used as an anti-inflammatory and antiviral treatment to help patients diagnosed with the novel coronavirus. Subscribe to CNBC PRO for access to investor and analyst insights: https://cnb.cx/2Vtntx6 Veru shares surged double digits to new highs Monday after the oncology biopharmaceutical company released positive data about a cancer drug being studied to help fight Covid-19. The Miami-based company, which develops drugs for breast and prostate cancer, disclosed that a prostate cancer treatment yielded positive efficacy and safety results in a Phase 2 clinical trial in hospitalized patients suffering from acute respiratory distress syndrome caused by Covid-19. The oral drug, called VERU-111, showed an 82% reduction in deaths or respiratory failure almost 30 days after treatment, compared to patients receiving a placebo, Veru announced. Dr. Mitchell Steiner, CEO of Veru, told CNBC’s Jim Cramer that the cancer medicine can serve as both an anti-inflammatory and antiviral against the sometimes deadly respiratory disease. “We were able to show some real hard endpoints,” he said in a “Mad Money” interview. “For example, a hard endpoint is death and so we showed a reduction in death from 30% in the placebo arm to 5.3% in the treatment arm. So that, as you mentioned, that’s a reduction of 82%.” Veru is in line to meet with the U.S. Food and Drug Administration as part of its efforts to begin a Phase 3 clinical trial to study the drug’s impact on individuals with severe cases of Covid-19. About 200 hospitalized patients and high risk for acute respiratory distress syndrome are expected to participate in the next trial study. The Phase 2 trial included 40 patients and was carried out in five sites across the U.S. Veru hopes to begin the next clinical stage in April and to complete the trial in the fourth quarter of this year. The company said it would seek funding from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority to supply needs in the U.S., should the FDA approve the drug for usage. “We think if we can get started in April and be done by year-end, that’s record time and gives everybody the comfort that we have something here that’s got the robustness that will be required to go after patients that are the sickest and try to stave off death and respiratory failure,” Steiner said. Veru stock jumped nearly 28% during the trading day, closing at a record $13.92 for a $1 billion valuation. As of Monday evening, U.S. deaths of Covid-19 exceeded 464,800. » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: https://www.cnbc.com/2020/09/29/the-news-with-shepard-smith-podcast.html?__source=youtube%7Cshepsmith%7Cpodcast Connect with CNBC News Online Get the latest news: http://www.cnbc.com/ Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC https://www.cnbc.com/select/best-credit-cards/ #CNBC #CNBCTV

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.